Citigroup Inc Arbutus Biopharma Corp Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Citigroup Inc holds 187,720 shares of ABUS stock, worth $583,809. This represents 0.0% of its overall portfolio holdings.
Number of Shares
187,720
Previous 109,051
72.14%
Holding current value
$583,809
Previous $419,000
46.3%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ABUS
# of Institutions
165Shares Held
102MCall Options Held
649KPut Options Held
666K-
Morgan Stanley New York, NY22.6MShares$70.2 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.2MShares$41.2 Million22.74% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$35.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.98MShares$27.9 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.74MShares$27.2 Million4.68% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $466M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...